Anti-phospho - VEGFR2(pTyr1059) anticorps produit dans un anticorps isolé rabbit affinity

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

The immunoglobulin-like (Ig-like) domains of the vascular endothelial growth factor receptor-2 (VEGFR-2) are essential for specific ligand binding and receptor dimerization. It helps to activate multiple signaling cascades. VEGF participates in angiogenesis. VEGFR2 is involved in progression of several cancers like gliomas, malignant peripheral nerve sheath tumors, triple-negative breast cancer (TNBC) and gastrointestinal stromal tumors (GISTs).

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

General description

The vascular endothelial growth factor receptor-2 (VEGFR-2) is also called as kinase insert domain containing receptor (KDR). There are seven immunoglobulin-like (Ig-like) domains at the extracellular region (EC) of VEGFR-2. This gene is mapped to human chromosome 4q12.

Immunogen

Peptide sequence around phosphorylation site of tyrosine 1059 (P-D-Yp-V-R), according to the protein NP_002244.1

Physical form

Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol

Target description

Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi′s sarcoma lesions